Choice A rationale

A pain rating of 2/10 is not directly related to the therapeutic effect of Bisacodyl. Bisacodyl is a stimulant laxative used to treat constipation, and its effectiveness would not typically be measured by pain ratings20.

Choice B rationale

A non-blanchable red area could be a sign of a pressure ulcer or other skin condition. It is not a therapeutic result of Bisacodyl administration20.

Choice C rationale

Blood pressure of 135/81 mmHg is a normal reading and is not directly related to the therapeutic effect of Bisacodyl20.

Choice D rationale

Sinus tachycardia, or a faster-than-normal heart rate, is not a therapeutic result of Bisacodyl administration. If a patient experiences sinus tachycardia while taking Bisacodyl, they should seek medical attention20.

Choice E rationale

Itching in legs is not a therapeutic result of Bisacodyl administration. It could be a sign of an allergic reaction or other medical condition20.

Choice F rationale

Semifluid stool is the correct answer. Bisacodyl is a stimulant laxative that works by increasing activity in the intestines to cause a bowel movement. Therefore, the production of semifluid stool can be considered a therapeutic result of Bisacodyl administration20.

Choice G rationale

A burning sensation is not a therapeutic result of Bisacodyl administration. If a patient experiences a burning sensation while taking Bisacodyl, they should seek medical attention20.

Choice A rationale

Montelukast does not increase the production of mucus in the lungs. In fact, it helps to reduce inflammation and may be used to prevent asthma attacks.

Choice B rationale

Montelukast is a leukotriene modifier that helps to reduce inflammation and prevent asthma attacks and exercise-induced bronchoconstriction. It works by blocking the action of leukotriene D4 in the lungs resulting in decreased inflammation and relaxation of smooth muscle. This prophylactic limitation of the inflammatory response to allergens is a key function of montelukast.

Choice C rationale

Montelukast does not contract the smooth muscles located in the respiratory tract. Instead, it helps to relax the smooth muscles in the lungs, reducing inflammation and making it easier to breathe.

Choice D rationale

Montelukast does not directly repair damaged tissue in the base of the lungs. Its primary function is to prevent and manage symptoms of asthma and allergies by reducing inflammation in the airways.